Acute myeloid leukemia (AML) Cancer Acute myeloblastic leukaemia [AML]
Conditions
Interventions
The study involved AML patients (except APL patients) from different Hematology departments in different hospitals at Heilongjiang Province in China. All the treatment centers follow the same treatmen
Sponsors
Heilongjiang Institute for Hematology and Oncology Research (China)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Any age AML patients (except APL) at different treatment stages, who are responsive or non-responsive to conventional treatments are all included in this trial 2. Patients agreed to receive the treatment
Exclusion criteria
Exclusion criteria: 1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc.) 2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc.) 3. Illegal drug use or chronic alcoholism 4. Physical limitations, mental or intellectual disabilities 5. Any condition that may affect the development of this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient disease-free survival and overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patient drug concentrations 2. Patient AML burden during each treatment period 3. Drug side effects evaluation 4. Patient relapse-free survival 5. Patient overall survival To monitor the primary and secondary clinical outcomes, patients' peripheral blood and bone marrow samples were tested at diagnosis, and at the end of each treatment cycle: blood cell count and staining, flow cytometry, RT-PCR and in-situ hybridization are used to test cell morphology, gene mutations, and cytogenetic changes. | — |
Countries
China
Outcome results
None listed